ARIUS announces cancer stem cell antibody program successfully completes first toxicology study



    
    -Lead antibody targeting novel epitope of CD44 found in breast, colon,
                            and prostate cancers-
    

    TORONTO, Oct. 23 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that the lead drug candidate from its CD44 Cancer Stem Cell
program has successfully completed its first toxicology study and has shown
good efficacy in animal models. ARIUS' program targets a novel epitope of CD44
that has been found in a number of cancer indications including breast, colon,
and prostate cancers. Two humanized versions of the CD44 targeting antibody
have been generated in preparation for the initiation of human clinical trials
in 2008.
    "To be effective against cancer, a treatment must eliminate the cancer
stem cells at the heart of the disease that are driving tumor growth and
seeding new tumors," said Dr. David Young, President and CEO. "Our CD44
targeting antibody is one of the most advanced drug candidates to target
cancer stem cells. CD44 is considered an especially attractive target for
anti-tumor drug discovery and development because it has been identified as a
cancer stem cell marker in breast, prostate and colon cancers. Having now
successfully completed our initial CD44 toxicology study, we look forward to
moving our CD44 antibody toward human clinical trials in 2008."

    Toxicology Presentation

    ARIUS has demonstrated that its antibody targets a novel epitope of CD44
that is present on the majority of human tumors. A dose-ranging pilot
toxicology study in non-human primate models demonstrated no dose-limiting
toxic effects at doses up to 95 mg/kg. Effects observed in healthy animals
were minor and transient.
    Additional information can be found at AACR-NCI-EORTC 2007 International
Conference on Molecular Targets and Cancer Therapeutics in San Francisco at
the following location and times: Abstract B41: "Toxicology and
pharmacokinetics of chimeric ARH460-16-2, a therapeutic monoclonal antibody
targeting CD44." Session B, Wednesday, October 24, 2007, between
12:30-2:30 p.m. and 5:30-7:30 p.m.

    Efficacy Presentation

    ARIUS' CD44 targeting antibody has demonstrated significant tumor growth
inhibitory activity in in vivo animal models of breast, prostate, liver, and
AML cancers. In breast cancer models, the antibody demonstrated tumor
regression with increased survival at all doses. Two humanized versions of the
antibody have been generated and their affinity is comparable to that of the
chimeric and murine antibodies. The results of this study have also
demonstrated the potential for the antibody to target the cancer stem cell
antigen in breast cancer. The potency of the two humanized antibodies on tumor
growth inhibition has been demonstrated in established tumor models in
preparation for human clinical trials in 2008.
    Additional information can be found at AACR-NCI-EORTC 2007 International
Conference on Molecular Targets and Cancer Therapeutics in San Francisco at
the following location and times: Abstract A74: "Chimeric and humanized
versions of the anti-CD44 monoclonal antibody ARH460-16-2 have potent
anti-tumor efficacy in established models of human breast and metastatic liver
cancer." Session A, Tuesday, October 23, 2007, between 12:30-2:30 p.m. and
5:30-7:30 p.m.

    About ARIUS

    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 400
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARIUS is listed on the TSX under the symbol "ARI". For further
information, visit www.ariusresearch.com

    Forward-Looking Statements

    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.





For further information:

For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,
wwhitehead@ariusresearch.com, contact@ariusresearch.com; James Smith, Investor
Relations, (416) 815-0700 ext. 229, jsmith@equicomgroup.com

Organization Profile

ARIUS RESEARCH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890